Assertio

ASRT

Market cap $152M

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Assertio Holdings, Inc. (NasdaqCM: ASRT) to Garda Therapeutics. Under the terms of the proposed transaction, shareholders of Assertio will receive $18.00 per share in cash and a contingent value right. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

MILWAUKEE, May 13, 2026 /PRNewswire/ -- Ademi LLP is investigating Assertio (NASDAQ: ASRT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Zydus. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, following an engagement process outlined under the revised merger agreement (the “Garda Merger Agreement”) with Garda Therapeutics, Inc. (“Garda”), the Company's Board of Directors (the “Board”) approved a definitive agreement with Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited (“Zydus”) to acquire all outstanding shares of Assertio common stock for $2.

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the “Garda Agreement”) to be acquired by Garda for $21.80 per shar.

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to postpone the commencement of the previously announced tender offer to acquire all outstanding shares of Assertio to May 8, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the “Garda Agreement”) to be acquired by Garda for $21.80.

Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, on May 1, 2026, Assertio and Garda Therapeutics (“Garda”) entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Garda has increased its offer to acquire all outstanding shares of Assertio to $21.80 per share in cash with no contingent value right. The increased offer represents a 21.1% premium to Garda's original o.

Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to extend the deadline to commence the previously announced tender offer to acquire all outstanding shares of Assertio to May 4, 2026. As previously announced on April 8, 2026, Assertio has entered into a definitive agreement (the “Garda Agreement”) to be acquired by Garda for $18.00 per share in.

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today provided an update that Garda Therapeutics, Inc. (“Garda”) intends to commence the tender offer to acquire all outstanding shares of Assertio on April 29, 2026 – the day following the expiration of the 20-day “window-shop” period. As previously announced on April 8, 2026, Assertio has entered into a definitive agreement (the “Garda Agreement”) to be acquired by Garda for $18.00 per sh.